News OEM

Biomaterials for Osteocalcin immunoassay development & manufacturing

Supporting your immunoassay portfolio expansion

March 27, 2024

 

Osteocalcin is a small protein composed by 49 amino acids and is also known as bone gamma-carboxylation. 

Osteocalcin is the most abundant non-collagenous protein in bone and is synthesized by mature osteoblasts, odontoblasts, and hypertrophic chondrocytes. The main role of osteocalcin is in metabolic regulation, bone mineralization and calcium ion homeostasis1.

In clinical laboratories, serum levels of osteocalcin are considered a marker of osteoblast function for the assessment of bone formation2 and, alongside other parameters, may be useful for assessing osteoporosis1. Osteoporosis is a clinical condition that can lead to impaired bone strength and loss of bone mass, increasing the risk of fractures due to the deterioration of bone tissue and disruption of bone microarchitecture3. Osteoporosis is the most common bone disease in humans, with an estimated worldwide prevalence of 18.3%4.

How Werfen can support you 

We can support your immunoassay portfolio expansion in the bone metabolism panel by providing antibodies for the development and manufacturing of immunoassays to determine Osteocalcin.

Werfen Bone metabolism biomaterials portfolio consists of the following products

Biomaterial

PN

Product Description

Antibody

3000-7072

Anti-Osteocalcin mAb (OST18m)

3000-7073

Anti-Osteocalcin mAb (OST24m)

 

 

 


 

 

Contact us for further information on product availability and development stage

 

 

 

 

 

 

 

 

 

 

[1] Rong Kuo et al. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Research. 2017

[2] Jinqiao et al. An overview of osteocalcin progress. The Japanese Society for Bone and Mineral Research. 2016

[3] Sözen et al. An overview and management of osteoporosis. European Journal of Rheumatology. 2016

[4] Salari et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. 2021

 

Share Press Release:

LinkedIn twitter facebook
Contact us

Please contact us directly via telephone or with the following form.

Tel. +34 93 860 90 00

DATA PROTECTION POLICY:

Biokit, S.A. and Biokit Research & Development, S.L.U. will process your personal data to respond to your requests for information or support, or to understand your needs and provide you with a better service relying on our legitimate interest to do so. You can find more information about our data privacy practices and how to exercise your rights in our Privacy Policy. You can also contact us at DPO-biokit@werfen.com.